Clinical trial NCT02484911 - References

Chemotherapy-induced Nausea and Vomiting — Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting

Citation(s)

•   Andrews PL, Naylor RJ, Joss RA
  Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies. Support Care Cancer. 1998 May;6(3):197-203. Review.
•   Diemunsch P, Grélot L
  Potential of substance P antagonists as antiemetics. Drugs. 2000 Sep;60(3):533-46. Review.
•   Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY
  Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern Med J. 2013 Jan;43(1):73-6. doi: 10.1111
•   Grunberg SM, Hesketh PJ
  Control of chemotherapy-induced emesis. N Engl J Med. 1993 Dec 9;329(24):1790-6. Review.
•   Grunberg SM, Slusher B, Rugo HS
  Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2013 Feb;11(2 Suppl 1):1-18; quiz 2 p following 18. Review.
•   Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ
  Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor anta
•   Matsuki N, Torii Y, Saito H
  Effects of iron and deferoxamine on cisplatin-induced emesis: further evidence for the role of free radicals. Eur J Pharmacol. 1993 Dec 1;248(4):329-31.
•   Navari RM, Gray SE, Kerr AC
  Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011 Sep-Oct;9(5):188-95. doi: 10.1016/j.suponc.2011.05.002.
•   Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D
  Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009 Sep 23;28:131. doi: 10.1186/1756-9966-28-131.
•   Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, Hale JJ, Mills SG, Finke PE, MacCoss M, Sadowski S, Ber E, Cascieri M, Hill RG, MacIntyre DE, Hargreaves RJ
  The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology. 2000 Feb 14;39(4):652-63.

Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial

Details for clinical trial NCT02484911